Chinese red yeast rice inhibition of prostate tumor growth in SCID mice

Cancer Prevention Research

Volumn 4, Issue 4, 2011, Pages 608-615

  Hong, Mee Young ^a   Henning, Susanne ^a   Moro, Aune ^a   Seeram, Navindra P ^b   Zhang, Yanjun ^a   Heber, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CHOLESTEROL; CHOLESTIN; MEVINOLIN; PROSTATE SPECIFIC ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SCID MOUSE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL PRODUCTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLESTEROL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LOVASTATIN; MALE; MICE; MICE, SCID; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955852408     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0219     Document Type: Article

References (51)

1. American Cancer Society, Cancer facts and figures2010. Available from: www.cancer.org.
2. Attard G, Sarker D, Reid A, Molife R, Parker C, de Bono JS. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer 2006;95:767-74. (Pubitemid 44498089)
3. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9. (Pubitemid 38524696)
4. Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 1998;12:941-53. (Pubitemid 30660662)
5. Zhang L, Johnson M, Le KH, Sato M, Ilagan R, Iyer M, et al. Interrogating androgen receptor function in recurrent prostate cancer. Cancer Res 2003;63:4552-60. (Pubitemid 36951029)
6. Jariwala U, Prescott J, Jia L, Barski A, Pregizer S, Cogan JP, et al. Identification of novel androgen receptor target genes in prostate cancer. Mol Cancer 2007;6:39-53.
7. Kim D, Gregory CW, French FS, Smith GJ, Mohler JL. Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft. Am J Pathol 2002;160:219-26. (Pubitemid 34052282)
8. Ma J, Li Y, Ye Q, Li J, Hua Y, Ju D, et al. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 2000;48:5220-5
9. Wang HL, Fang SL. Indigenous fermented foods of non-western origin. In: Hesseltine CW, Wang HL, editors. Lubrecht & Cramer Ltd., Port Jervis, NY. Mycologica Memoirs; 1986. p. 317-44.
10. Simg R-H. "Tien-Kung K'ai-Wu" Chinese technology in the seventeenth century. Pennsylvania State University Press, University Park; 1996. p. 292-4.
11. Stuart MD. Chinese material medica: vegetable kingdom. Taipai, Republic of China: Southern Materials Center; 1979.
12. Li Z, Seeram NP, Lee R, Thames G, Minutti C, Wang HJ, et al. Plasma clearance of lovastatin versus Chinese red yeast rice in healthy volunteers. J Altern Complement Med 2005;11:1031-8. (Pubitemid 43134053)
13. Heber D, Lembertas A, Lu Q-Y, Bowerman S, Go VLW. An analysis of nice proprietary Chinese Red Yeast Rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med 2001;7:133-9. (Pubitemid 32319321)
14. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999;69:231-6. (Pubitemid 29065544)
15. Bravi F, Scotti L, Bosetti C, Talamini R, Negri E, Montella M, et al. Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer. Ann Oncol 2006;17:1014-7. (Pubitemid 43778996)
16. Cyrus-David MS, Weinberg A, Thompson T, Kadmon D. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 2005;173:1923-5. (Pubitemid 40675212)
17. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005;162:318-25.
18. Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Kurko B, et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 2005;66:1150-4. (Pubitemid 41797279)
19. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 2010;28:2653-9.
20. Katz MS, Carroll PR, Cowan JE, Chan JM, D'Amico AV. Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU Int 2010;106:627-32.
21. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-42. (Pubitemid 41766782)
22. Moorman PG, Hamilton RJ. Statins and cancer risk: what do we know and where do we go from here? Epidemiology 2007;18:194-6.
23. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S. Statin use and the risk of breast and prostate cancer. Epidemiology 2002;13:262-7. (Pubitemid 34415845)
24. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98:1819-25. (Pubitemid 46017933)
25. Hong MY, Seeram NP, Zhang Y, Heber D. Chinese red yeast rice versus lovastatin effects on prostate cancer cells with and without androgen receptor overexpression. J Med Food 2008;11:657-66.
26. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999;81:242-51. (Pubitemid 29423702)
27. Devgan SA, Henderson BE, Yu MC, Shi CY, Pike MC, Ross RK, et al. Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Prostate 1997;33:9-12. (Pubitemid 27381588)
28. Fung KM, Samara EN, Wong C, Metwalli A, Krlin R, Bane B, et al. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/ type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 2006;13:169-80.
29. Torres JM, Ruiz E, Ortega E. Development of a quantitative RT-PCR method to study 5alpha-reductase mRNA isozymes in rat prostate in different androgen status. Prostate 2003;56:74-9. (Pubitemid 36613158)
30. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.
31. Steers WD. 5alpha-reductase activity in the prostate. Urology 2001;58:17-24.
32. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The Influence of Finasteride on the Development of Prostate Cancer. N Engl J Med 2003;349:215-24. (Pubitemid 36859473)
33. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991;51:3753-61.
34. Hong MY, Bancroft LK, Turner ND, Davidson LA, Murphy ME, Carroll RJ, et al. Fish oil decreases oxidative DNA damage by enhancing apoptosis in rat colon. Nutr Cancer 2005;52:166-75. (Pubitemid 41579759)
35. Holt PR, Moss SF, Kapetanakis AM, Petrotos A, Wang S. Is Ki-67 a better proliferative marker in the colon than proliferating cell nuclear antigen? Cancer Epidemiol Biomarkers Prev 1997;6:131-5.
36. Hong MY, Seeram NP, Zhang Y, Heber D. Anti-cancer effects of Chinese red yeast rice versus monacolin K alone on colon cancer cells. J Nutr Biochem 2008;19:448-58. (Pubitemid 351783405)
37. Hall SA, Page ST, Travison TG, Montgomery RB, Link CL, McKinlay JB. Do statins affect androgen levels in men? Results from the Boston area community health survey. Cancer Epidemiol Biomarkers Prev 2007;16:1587-94. (Pubitemid 47294823)
38. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005;115:959-68. (Pubitemid 40489400)
39. Solomon KR, Freeman MR. Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab 2008;19:113-21.
40. Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control 2010;21:61-8.
41. Pelletier G, Luu-The V, El-Alfy M, Li S, Labrie F. Immunoelectron microscopic localization of 3b-hydroxysteroid dehydrogenase and type 5 17β-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J Mol Endocrinol 2001;26:11-9. (Pubitemid 32125118)
42. Hong MY, Seeram NP, Heber D. Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgenreceptor. J Nutr Biochem 2008;19:848-55.
43. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009;138:245-56.
44. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45. (Pubitemid 33741879)
45. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001-15. (Pubitemid 34728896)
46. Grossman ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen refractory prostate cancer. J Natl Cancer Inst 2001;93:1687-97. (Pubitemid 33130257)
47. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. CancerTreat Rev 2004;30:609-41. (Pubitemid 39451828)
48. Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med 2004;229:567-85. (Pubitemid 38878903)
49. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005;115:959-68. (Pubitemid 40489400)
50. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fnneb V. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med. 2006 Nov 23;1:4.
51. Venero CV, Venero JV, Wortham DC, Thompson PD. Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol 2010;105:664-6.